Monthly Archives: April 2017
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients
Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorectal tumors without RAS mutations. However, EGFR inhibitors are ineffective in these patients, and tumor level of EGFR does not asso… Continue reading
Association of RNASET2 Gene Polymorphisms with Decreased Expression and Clinical Characteristics of Severity in Crohn’s Disease
Variants in the tumor necrosis factor superfamily member 15 gene (TNFSF15, also called TL1A) have been associated with risk for inflammatory bowel diseases (IBD). TL1A affects expression of multiple cytokines to promote mucosal inflammation. Little is … Continue reading
Association of RNASET2 Gene Polymorphisms with Decreased Expression and Clinical Characteristics of Severity in Crohn’s Disease
Variants in the tumor necrosis factor superfamily member 15 gene (TNFSF15, also called TL1A) have been associated with risk for inflammatory bowel diseases (IBD). TL1A affects expression of multiple cytokines to promote mucosal inflammation. Little is … Continue reading
Supplementation of Diet with Galacto-oligosaccharides Increases Bifidobacteria, but not Insulin Sensitivity, in Obese Prediabetic Individuals
The gut microbiota affects host lipid and glucose metabolism, satiety, and chronic low-grade inflammation to contribute to obesity and type 2 diabetes. Fermentation end products, in particular the short-chain fatty acid (SCFA) acetate, are believed to … Continue reading
SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin
The canonical Wnt signaling pathway activates the transcriptional activity of β-catenin. This pathway is often activated in colorectal cancer cells, but strategies to block it in tumors have not been effective. The SAM pointed domain containing ETS tr… Continue reading
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) following 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed … Continue reading
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn’s Disease: a Phase 2a Study
MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn’s disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. Continue reading
Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells
Fibroblasts that interact with cancer cells are called cancer-associated fibroblasts (CAFs)—they promote progression of different tumor types. We investigated the characteristics and functions of CAFs in diffuse-type gastric cancers (DGCs) by analyzi… Continue reading
Small Nucleolar Noncoding RNA SNORA23, Upregulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of SYNE2 to Promote Growth and Metastasis of Xenograft Tumors in Mice
Small nucleolar noncoding RNAs (snoRNAs) regulate function of ribosomes, and specific snoRNAs are dysregulated in some cancer cells. We investigated dysregulation of snoRNAs in pancreatic ductal adenocarcinoma (PDAC) cells. Continue reading
Advances in Obesity: Causes, Consequences and Therapy
Obesity is a complex chronic disease that has become a major public health problem in many countries throughout the world because of its high prevalence, causal relationship with many serious medical illnesses, adverse effects on quality-of-life, and m… Continue reading